Shin Nippon Biomedical Laboratories Ltd. 13D and 13G filings for Satsuma Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-06-08 09:17 am Sale | 2023-06-08 | 13D | Satsuma Pharmaceuticals, Inc. STSA | Shin Nippon Biomedical Laboratories Ltd. | 1,000 100.000% | -2,793,113 (-99.96%) | Filing |
| 2023-04-17 4:09 pm Unchanged | 2023-04-16 | 13D | Satsuma Pharmaceuticals, Inc. STSA | Shin Nippon Biomedical Laboratories Ltd. | 2,794,113 8.400% | 0 (Unchanged) | Filing |
| 2021-03-31 08:52 am Purchase | 2021-02-26 | 13D | Satsuma Pharmaceuticals, Inc. STSA | Shin Nippon Biomedical Laboratories Ltd. | 2,794,113 8.900% | 2,794,113 (New Position) | Filing |